CLINICAL TRIALS PROFILE FOR REBECCAMYCIN
✉ Email this page to a colleague
Clinical Trials for Rebeccamycin
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00003737 ↗ | Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma. |
NCT00003737 ↗ | Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating children who have relapsed or refractory neuroblastoma. |
NCT00004189 ↗ | Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | Phase I trial to study the effectiveness of rebeccamycin analog and cisplatin with or without filgrastim in treating patients who have advanced cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. |
NCT00005027 ↗ | Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer. |
NCT00005027 ↗ | Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer | Completed | Barbara Ann Karmanos Cancer Institute | Phase 2 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer. |
NCT00005085 ↗ | Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have metastatic or locally recurrent colorectal cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. |
NCT00005817 ↗ | Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | Randomized phase II trial to compare the effectiveness of two regimens of rebeccamycin analogue in treating women who have stage IIIB or stage IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. The best way to give rebeccamycin analog in breast cancer patients is not yet known |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Rebeccamycin
Condition Name
Clinical Trial Locations for Rebeccamycin
Trials by Country
Clinical Trial Progress for Rebeccamycin
Clinical Trial Phase
Clinical Trial Sponsors for Rebeccamycin
Sponsor Name